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Spectral karyotyping is a diagnostic tool that allows visualization of chromosomes in different colors using the FISH
technology and a spectral imaging system. To assess the value of spectral karyotyping analysis for identifying
constitutional supernumerary marker chromosomes or derivative chromosomes at a national reference laboratory,
we reviewed the results of 179 consecutive clinical samples (31 prenatal and 148 postnatal) submitted for spectral
karyotyping. Over 90% of the cases were requested to identify either small supernumerary marker chromosomes
(sSMCs) or chromosomal exchange material detected by G-banded chromosome analysis. We also reviewed clinical
indications of those cases with marker chromosomes in which chromosomal origin was identified by spectral
karyotyping. Our results showed that spectral karyotyping identified the chromosomal origin of marker
chromosomes or the source of derivative chromosomal material in 158 (88%) of the 179 clinical cases; the
identification rate was slightly higher for postnatal (89%) compared to prenatal (84%) cases. Cases in which the
origin could not be identified had either a small marker chromosome present at a very low level of mosaicism (<
10%), or contained very little euchromatic material. Supplemental FISH analysis confirmed the spectral karyotyping
results in all 158 cases. Clinical indications for prenatal cases were mainly for marker identification after
amniocentesis. For postnatal cases, the primary indications were developmental delay and multiple congenital
anomalies (MCA). The most frequently encountered markers were of chromosome 15 origin for satellited
chromosomes, and chromosomes 2 and 16 for non-satellited chromosomes. We were able to obtain pertinent
clinical information for 47% (41/88) of cases with an identified abnormal chromosome. We conclude that spectral
karyotyping is sufficiently reliable for use and provides a valuable diagnostic tool for establishing the origin of
supernumerary marker chromosomes or derivative chromosomal material that cannot be identified with standard
cytogenetic techniques.
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Introduction
Spectral karyotyping is an invaluable diagnostic tool in
constitutional studies for identifying marker chromo-
somes and chromosomal exchanges that are not fully
defined by conventional cytogenetic methods [1,2]. This
is especially true in cases involving de novo small super-
numerary marker chromosomes (sSMCs) and derivative
chromosomes [3-6]. Such definitive karyotyping is
important in assessing risk for phenotypic abnormalities,
especially for prenatal situations [7,8]. The ability to
identify the origin of additional genetic materials is very
important for providing information to couples in
regard to the potential phenotypic and/or developmental
effect of a de novo rearrangement. Similarly, in evalua-
tion of infertility, the identification of derivative chro-
mosomal material may shed light on the mechanism of
infertility [9,10].
Although spectral karyotyping was developed more
than a decade ago, few large-scale studies have assessed
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rearrangements initially identified with conventional
GTG-banding (G-banding) cytogenetic analysis. The pri-
mary aim of this study was to assess the utilization of
spectral karyotyping for resolving chromosome abnorm-
alities that are not well delineated by conventional G-
banding.
Materials and methods
Spectral Karyotyping Analysis of Abnormalities not
resolved with Conventional Chromosome Analysis
We reviewed the results of spectral karyotyping and
confirmatory FISH testing performed on 179 consecu-
tive clinical specimens (31 prenatal and 148 postnatal
specimens) submitted to our national reference labora-
tory. In both prenatal and postnatal settings, the most
common indication for spectral karyotyping analysis was
the presence of chromosomal material not defined by
conventional G-banding. Chromosomal abnormalities
included unidentified marker chromosomes, additional
rearranged material of unknown origin, ring chromo-
somes, and various complex rearrangements.
Spectral Karyotyping Assay Procedure
The spectral karyotyping assay protocol recommended
by the vendor (Applied Spectral Imaging, Carlsbad, CA)
was followed. Emphasis was placed on the examination
of telomeric regions. Spectral karyotyping was per-
formed on metaphase chromosomes prepared for rou-
tine cytogenetic study from peripheral blood, amniotic
fluid, and chorionic villus sampling(CVS) using standard
hybridization procedures [1]. Equipment included the
SKY Vision Cytogenetic Workstation with a Spectra-
Cube
® and Sagnac interferometer, CCD camera for
image capture, and a computer system for image analy-
sis and pseudo-color karyotyping (Applied Spectral Ima-
ging). The resulting multicolor images were examined
with a 60x plan apochromatic objective followed by
Kodak color print documentation of pseudo-colored
karyotypes. All spectral karyotyping findings were con-
firmed by FISH using appropriate probes.
Results
Most of the 179 clinical samples were submitted to
further delineate additional material detected on G-
banded analysis. Overall, spectral karyotyping identified
the origins of the rearranged materials (including mar-
ker chromosomes) in 88% (158/179) of these cases; rates
were similar in prenatal and postnatal cases (84% vs.
89%; see Table 1). The abnormalities included supernu-
merary marker chromosome (75 cases), additional mate-
rial on a rearranged chromosome (71 cases), and ring
chromosome (13 cases); a variety of complex rearrange-
ments were observed in the remaining 20 cases. Spectral
karyotyping identified the origin of the additional mate-
rial in 77% to 100% of prenatal and postnatal samples,
depending on the type of rearrangement involved. Nota-
bly, spectral karyotyping resolved the G-banding ambi-
guities in 19 of the 20 cases (95%) with complex
rearrangements. Most cases in which the origin could
not be identified were characterized by either a small
marker chromosome present at a very low level of
mosaicism (< 10%), or by a very small abnormality (data
not shown). The lower practical limit of detection by
spectral karyotyping appears to be within a single
euchromatic band at a 500 band-level of resolution, or
6-10 Mb in size. Figures 1, 2, 3 and 4 illustrate the use
of spectral karyotyping in a variety of selected cases
with ambiguous GTG-banding results. Table 2 listed
clinical indications of 41 cases referred for further char-
acterization of sSMC and also other rearrangements by
spectral karyotyping. Clinical indications for prenatal
cases were mainly for marker identification after amnio-
centesis. For postnatal cases, the primary indications
were developmental delay and multiple congenital
anomalies (MCA). The most frequently encountered
markers were of chromosome 15 origin for satellited
chromosomes, and chromosomes 2 and 16 for non-
satellited chromosomes. We were able to obtain perti-
nent clinical information for 47% (41/88) of cases with
an identified abnormal chromosome.
Discussion
The findings of this study demonstrate the accuracy and
usefulness of spectral karyotyping in identifying deriva-
tive constitutional chromosomal material. Our findings
clearly demonstrate the clinical usefulness of spectral
karyotyping for resolving the origin of a marker chro-
mosome or rearranged chromosomal material when G-
banding analysis does not. Once the source has been
identified by spectral karyotyping, confirmatory testing
using FISH probes or family studies should follow. In
our series, these confirmatory studies verified informa-
tive spectral karyotyping results in all 158 cases. There-
fore, if further data support the accuracy of spectral
karyotyping, follow-up FISH testing may not always be
needed for confirmation. In comparison with array
CGH, spectral karyotyping is considered more valuable
when it is used to identify polyploidy (e.g., 69,XXX), the
origin of a marker chromosome in metaphase, or
balanced rearrangements such as translocations, pro-
vided that the size of the subtle rearrangement is at
least one-band size at a 500 band-level of resolution
[9,11]. Spectral karyotyping may also be advantageous
over array CGH when a low level of mosaicism (< 20%)
is suspected, when a complex karyotype is observed on
a conventional G-banded study, or when a DNA sample
is not attainable for array CGH as a part of the follow-
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karyotyping has limited ability to accurately measure the
size of a chromosomal rearrangement including sSMCs
and to precisely determine the chromosome regions or
breakpoints involved [9]. As such, spectral karyotyping
will not allow for an accurate correlation between a
chromosomal rearrangement and a specific phenotype.
It is through the effort made by Liehr et al. at Jena Uni-
versity of Germany since 2004 that a comprehensive
sSMC homepage http://www.uniklinikum-jena.de/fish/
sSMC.html has become available as an important refer-
ence source for the research community [14]. This
homepage is a regularly updated, freely available online
database with a focus to collect all available reported
small supernumerary marker chromosomes (sSMCs) for
Table 1 Spectral Karyotype Findings in 31 Prenatal Cases and 148 Postnatal Cases with Abnormal Karyotypes
Cytogenetic (GTG-banded) Abnormality Spectral Karyotype Findings
Positive, n Inconclusive, n Approximate Sensitivity, %
Supernumerary Marker
Prenatal (n = 13) 10 3 77
Postnatal (n = 62) 48 14 77
Additonal genetic material
Prenatal (n = 6) 5 1 83
Postnatal (n = 65) 63 2 97
Ring chromosome
Prenatal (n = 4) 4 0 100
Postnatal (n = 9) 9 0 100
Complex rearrangements
Prenatal (n = 8) 7 1 88
Postnatal (n = 12) 12 0 100
======================== ======== ========== =========
Total
Prenatal (N = 31) 26 5 84
Postnatal (N = 148) 132 16 89
Figure 1 A supernumerary ring marker originating from
chromosome 16. The sample tested was amniotic fluid. Banded
metaphase (left) and spectral karyotype (right) are shown. Marker
origin was confirmed by FISH using a chromosome 16 centromeric
probe (not shown).
Figure 2 A supernumerary bisatellited marker originating from
chromosome 22 detected in a peripheral blood sample from a
2-year-old boy. Banded metaphase (left) and spectral karyotype (right)
are shown. Marker origin was confirmed by FISH using probes for 14/22
centromeres and the TUPLE1 gene locus (22q11.2) (not shown).
Figure 3 An insertion of genetic material from chromosome 9
into chromosome 6. The sample tested was peripheral blood from
a 1-year-old boy. Banded metaphase (left) and spectral karyotype
(right) are shown. The insertion was confirmed by FISH using
painting probes specific for chromosomes 6 and 9 (not shown).
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counseling.
In the 41 referral cases available for collection of
further clinical information in our series, clinical indi-
cations were different between pre- and post-natal
cases. While clinical indications were mainly for mar-
ker characterization after amniocentesis among prena-
tal cases, developmental delay and multiple congenital
anomalies were the two major indications in our post-
natal cases. Our data showed that the most frequently
encountered markers were of chromosome 15 origin
for satellited chromosomes, and chromosomes 2 and
16 for non-satellited chromosomes. These data are
consistent with those published by Liehr et al [14].
Due to our unique setting as a national reference
laboratory, we were only able to obtain pertinent clini-
cal information for 47% (41/88) of cases with an iden-
tified abnormal chromosome.
Besides spectral karyotyping, there are many other
approaches that are available for sSMC characterization.
These approaches include centromere-specific multico-
lor FISH (cenM-FISH), subcentromere-specific multico-
lor (subcenM-FISH), microdissection and reverse FISH,
microdissection and arrayC G H ,o ra r r a yC G Ha l o n e
[14-18]. For other complex rearrangements, many possi-
bilities are also accessible for further delineation after
the chromosomal origin has been identified. These
include BAC-FISH and FISH-banding methodologies
such as multicolor banding fluorescence in situ hybridi-
zation (MCB/m-banding) up to array-CGH (microarray-
based comparative genomic hybridization) in case of
unbalanced rearrangements [16,18].
In recent years, array-CGH has attracted a great deal
of research interest and is now considered an efficient
and sensitive technique for detecting genome-wide copy
number alterations at high resolution. It has increasingly
replaced the role of spectral karyotyping in the
diagnostic arena to identify the origin of sSMCs and
other rearrangements, and also to characterize complex
sSMCs. However, spectral karyotyping, to our belief, will
still hold its unique value in the market place as a useful
diagnostic tool, especially in identifying complex rear-
rangements in metaphase.
T h ed a t ap r e s e n t e dh e r ea n di nt h el i t e r a t u r ed on o t
support the use of spectral karyotyping as a primary
diagnostic tool in prenatal situations, as the risk of
misdiagnosis is still a major concern [7,8]. Yaron et al.
tested the application of spectral karyotyping for char-
acterizing de novo small supernumerary marker chro-
mosomes (sSMCs) during prenatal diagnosis [7]. In
this series, the evaluation of ring chromosomes and
non-satellited SMCs benefited greatly from the addi-
tional analysis; however, spectral karyotyping did not
provide further information for characterization in two
cases with bisatellited SMCs [7]. Besides, spectral kar-
yotyping results, unlike array CGH, often need to be
refined by the use of FISH probes. Therefore, Heng et
al. proposed a strategy that combines G-banding, spec-
tral karyotyping and FISH for pre- and post-natal
chromosomal analysis [11]. This strategy involves rou-
tine G-banding for the initial evaluation, but any mar-
ker chromosomes or complex rearrangements thus
detected are further characterized by spectral karyotyp-
ing and then verified with FISH. Our findings provide
evidence that this strategy is efficient for pre- and
postnatal analysis. In this regard, Liehr et al. (2009)
also proposed a different approach that uses only FISH
methologies to handle sSMC cases in prenatal situa-
tions [14].
In the foreseeable future, spectral karyotyping in
conjunction with array CGH will continue to be
applied not only in constitutional chromosome studies,
but also in cancer cytogenetic studies for identification
of complex and cryptic rearrangements [19]. Knowing
that chromosomal changes in cancer are often consid-
ered a useful reference for therapy design, these chro-
mosomal changes must be elucidated as precisely as
possible. To provide better care for cancer patients,
spectral karyotyping in combination with other mole-
cular cytogenetic methodologies such as FISH and
array CGH should be useful for supplementing G-
banding analysis for the identification of significant
prognostic rearrangements.
In conclusion, our findings describe the validation of
spectral karyotyping in a national-wide commercial cyto-
genetics laboratory and its successful introduction into
the diagnostic arena. This technology provides a valu-
able diagnostic tool for establishing the origin of small
supernumerary marker chromosomes (sSMCs) and deri-
vative chromosomal material that cannot be identified
with standard techniques.
Figure 4 Spectral karyotype analysis identified origins of
multiple (3-6) markers present in a 3-year-old girl. The sample
was peripheral blood. Banded metaphase (left) and spectral
karyotype (right) are shown. Spectral karyotype analysis indicated
that the markers were respectively derived from chromosomes 12,
19, 21, 22, and X.
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Case
number
Sex Age Type of Study Result Clinical indication
F0414116 M Prenatal Prenatal (AF) der(1) Supernumerary mosaic marker found elsewhere at amniocentesis, Parental chromosome
studies reported as normal (studied elsewhere)
F0425680 F Prenatal Prenatal (CVS) der(2) Advanced maternal age
F0439968 M 1Y Neonatal r(2) Developmental delay
F0533491 F 10Y Postnatal der(2) Short stature, Pituitary dwarfism
F0549217 M 19M Postnatal der(2) Delayed milestones, Multiple congenital anomalies
F0613262 M 2Y Postnatal der(3) Developmental delay
F0732043 M 2Y Postnatal der(3) Delayed milestones
F043725 M 2Y Postnatal der(7) Prenatal ultrasound with an unspecified kidney abnormality; AF study with a result of 47,XY
+mar[3]/46,XY[27]
F0451268 M 1Y Neonatal r(8) 47,XY,+r/46,XY (diagnosed elsewhere)
F0633932 M 2Y Postnatal der(9) Developmental delay
F0713569 F 6M Neonatal i(9)(p10) Macroglossia
F0716379 F 11Y Postnatal der(9) Velocardiofacial (VCF) phenotype; NF1 diagnosis; Congenital cataract, Developmental delay,
Abnormal aortic valve
F0646031 F Prenatal Prenatal (AF) der(12) Advanced maternal age
F0445519 M 2Y Postnatal der(14
or 22)
Developmental delay
F0519414 F 12Y Postnatal der(14
or 22)
Ataxia; Rule out 47,XXX
F058133 M Prenatal Prenatal (AF) der(15) Advanced maternal age; Amniocentesis study had a result of 47,XY,+mar[8]pat/46,XY[2]
F0554133 F 12Y Postnatal der(15) Short stature
F0621647 F 12Y Postnatal r(15) Previous study performed elsewhere
F0642559 F 3Y Postnatal psu idic
(15)
Rule out SRY deletion
F0658799 M 6Y Postnatal idic(15) Pervasive developmental disorder
F077829 M 25Y Postnatal der(15) Infertility
F047204 F 33Y Postnatal r(16) Multiple miscarriages
F0548089 F 2M Neonatal der(16) Prenatal karyotype of 47,XX,+mar[7]/46,XX[12] (performed elsewhere)
F0616779 F 2Y Postnatal r(16) Seizures
F0751841 F Prenatal Prenatal (AF) der(16) Advanced maternal age
F04635 F 7Y Postnatal der(18) Previous blood study showed mosaicism for a small marker chromosome
F0528563 M 2M Neonatal der(18) Multiple congenital anomalies; A ring chromosome detected at prenatal diagnosis
F077572 F Prenatal Prenatal (AF) der(18) Mosaic fetal karyotype of 47,XX,+mar[8]/46,XX[7] reported elsewhere; Advanced maternal age
F0534481 F 35D Neonatal der(19) Amniotic fluid study had a karyotype of 47,XX,+mar
F0628560 F 2Y Postnatal r(19) Multiple congenital anomalies
F0642312 F 12Y Postnatal der(19) Rule out Fragile × syndrome
F0549359 N/
G
10Y Postnatal der(20) Developmental delay, Autism
F0819257 F 8Y Postnatal der(20) Mental retardation/developmental delay, Trigonocephaly
F067630 F 11Y Postnatal r(21) Dermatitis, Acquired acanthosis nigricans
F0535997 M 35Y Postnatal der(22) Unspecified anterior pituitary hyperfunction, Chronic lymphocytosis, Thyroiditis, Hirsutism,
Celiac disease, Disorders of iron metabolism.
F0560040 F 27Y Postnatal dic(22) Bone marrow aspirate: agranulocytosis, neutropenia and borderline anemia; Blood specimen:
agranulocytosis; To rule out a constitutional marker chromosome
F0636127 M 1Y Postnatal der(22) Developmental delay
F0636122 M N/G Postnatal der(22) Rule out Trisomy 13
F0646601 F 11Y Postnatal idic(22) Delayed milestones, Multiple congenital anomalies
F0845840 F 1D Neonatal der(22) Microcephaly
F0851097 F 20Y Postnatal der(22) Congenital heart defect
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